Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE) announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trader Talk Trading Halts

Vitae Pharmaceuticals (VTAE) PT Raised to $23 at WedbushMarch 18, 2016 6:42 AM JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market OutperformMarch 17, 2016 9:33 AM Stifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PTMarch 17, 2016 6:27 AM Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe PsoriasisMarch 16, 2016 4:05 PM